Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Novo Nordisk AS のコンセンサス目標株価は $80.72 で、16 人のアナリストの評価に基づいています。最高値は $160(11 6, 2024 に Cantor Fitzgerald が発表)、最安値は $31(3 28, 2023 に BTIG が発表)です。直近のアナリスト評価 3 件は CICC、Goldman Sachs、BMO Capital により 1 9, 2026、11 28, 2025、11 25, 2025 に発表されました。CICC、Goldman Sachs、BMO Capital の平均目標株価は $57.83 で、これらの最新評価から Novo Nordisk AS に対して -7.82% のdownsideが示唆されています。
1アナリスト評価から算出
| Buy Now | Get Alert | ||||||
|---|---|---|---|---|---|---|---|
| 01/09/2026 | Buy Now | 17.15% | CICC | → $73.5 | Initiates | → Outperform | Get Alert |
| 12/08/2025 | Buy Now | — | Argus Research | — | Downgrade | Buy → Hold | Get Alert |
| 11/28/2025 | Buy Now | -13.93% | Goldman Sachs | $60 → $54 | Maintains | Buy | Get Alert |
| 11/25/2025 | Buy Now | -26.68% | BMO Capital | $50 → $46 | Maintains | Market Perform | Get Alert |
| 11/24/2025 | Buy Now | — | HSBC | — | Downgrade | Buy → Hold | Get Alert |
| 10/27/2025 | Buy Now | — | Jefferies | — | Assumes | Underperform → Underperform | Get Alert |
| 10/14/2025 | Buy Now | -12.33% | BMO Capital | $50 → $55 | Maintains | Market Perform | Get Alert |
| 10/02/2025 | Buy Now | 11.57% | HSBC | → $70 | Upgrade | Hold → Buy | Get Alert |
| 09/29/2025 | Buy Now | -25.09% | Morgan Stanley | $59 → $47 | Downgrade | Equal-Weight → Underweight | Get Alert |
| 09/17/2025 | Buy Now | — | Berenberg | — | Upgrade | Hold → Buy | Get Alert |
| 08/19/2025 | Buy Now | 11.57% | TD Cowen | $105 → $70 | Maintains | Buy | Get Alert |
| 08/05/2025 | Buy Now | — | UBS | — | Downgrade | Buy → Neutral | Get Alert |
| 07/31/2025 | Buy Now | — | HSBC | — | Downgrade | Buy → Hold | Get Alert |
| 07/30/2025 | Buy Now | — | Barclays | — | Downgrade | Overweight → Equal-Weight | Get Alert |
| 06/18/2025 | Buy Now | 67.36% | TD Cowen | $105 → $105 | Reiterates | Buy → Buy | Get Alert |
| 04/17/2025 | Buy Now | 2.01% | BMO Capital | $105 → $64 | Downgrade | Outperform → Market Perform | Get Alert |
| 01/08/2025 | Buy Now | — | UBS | — | Upgrade | Sell → Buy | Get Alert |
| 12/23/2024 | Buy Now | 67.36% | BMO Capital | $156 → $105 | Maintains | Outperform | Get Alert |
| 12/20/2024 | Buy Now | 67.36% | TD Cowen | $155 → $105 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | 155.03% | Cantor Fitzgerald | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 10/17/2024 | Buy Now | 148.65% | BMO Capital | $160 → $156 | Maintains | Outperform | Get Alert |
| 10/10/2024 | Buy Now | 155.03% | Cantor Fitzgerald | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 09/20/2024 | Buy Now | 155.03% | Cantor Fitzgerald | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 09/16/2024 | Buy Now | 155.03% | Cantor Fitzgerald | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 09/09/2024 | Buy Now | 155.03% | Cantor Fitzgerald | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 08/19/2024 | Buy Now | 155.03% | Cantor Fitzgerald | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 08/08/2024 | Buy Now | 155.03% | BMO Capital | $170 → $160 | Maintains | Outperform | Get Alert |
| 08/05/2024 | Buy Now | 155.03% | Cantor Fitzgerald | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 07/01/2024 | Buy Now | 155.03% | Cantor Fitzgerald | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 06/25/2024 | Buy Now | 159.81% | BMO Capital | $163 → $163 | Maintains | Outperform | Get Alert |
| 06/20/2024 | Buy Now | 155.03% | Cantor Fitzgerald | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 06/17/2024 | Buy Now | 155.03% | Cantor Fitzgerald | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 06/10/2024 | Buy Now | 155.03% | Argus Research | $125 → $160 | Maintains | Buy | Get Alert |
| 04/18/2024 | Buy Now | 155.03% | Cantor Fitzgerald | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 04/12/2024 | Buy Now | 159.81% | BMO Capital | → $163 | Initiates | → Outperform | Get Alert |
| 04/05/2024 | Buy Now | 155.03% | Cantor Fitzgerald | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 04/01/2024 | Buy Now | 155.03% | Cantor Fitzgerald | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 03/20/2024 | Buy Now | 155.03% | Cantor Fitzgerald | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 03/08/2024 | Buy Now | 155.03% | Cantor Fitzgerald | $140 → $160 | Maintains | Overweight | Get Alert |
| 02/20/2024 | Buy Now | 123.15% | Cantor Fitzgerald | $140 → $140 | Reiterates | Overweight → Overweight | Get Alert |
| 02/15/2024 | Buy Now | 123.15% | Cantor Fitzgerald | $140 → $140 | Reiterates | Overweight → Overweight | Get Alert |
| 02/14/2024 | Buy Now | 123.15% | Cantor Fitzgerald | $140 → $140 | Reiterates | Overweight → Overweight | Get Alert |
| 02/06/2024 | Buy Now | 115.18% | TD Cowen | $115 → $135 | Maintains | Outperform | Get Alert |
| 02/01/2024 | Buy Now | 99.24% | Argus Research | $115 → $125 | Maintains | Buy | Get Alert |
| 02/01/2024 | Buy Now | 123.15% | Cantor Fitzgerald | $120 → $140 | Maintains | Overweight | Get Alert |
| 01/23/2024 | Buy Now | 91.27% | Morgan Stanley | → $120 | Initiates | → Overweight | Get Alert |
| 12/04/2023 | Buy Now | 83.3% | TD Cowen | $105 → $115 | Maintains | Outperform | Get Alert |
| 12/01/2023 | Buy Now | 83.3% | Argus Research | $110 → $115 | Maintains | Buy | Get Alert |
| 12/01/2023 | Buy Now | 91.27% | Cantor Fitzgerald | → $120 | Initiates | → Overweight | Get Alert |
| 10/02/2023 | Buy Now | 75.33% | Argus Research | → $110 | Initiates | → Buy | Get Alert |
| 03/28/2023 | Buy Now | -50.59% | BTIG | $20 → $31 | Maintains | Buy | Get Alert |
Novo Nordiskの最新目標株価Novo Nordisk。(NYSE:NVO) の最新目標株価をCICCが1 9, 2026日に発表した。このアナリスト会社はNovo Nordisk ({{change}:{{mbol}}) {{{quoteName}}の{{change}:{{symbol}}からriseまで12ヶ月以内(17.15% upsideの可能性あり)と予想する$73.50の目標株価を設定しました。過去1年間に16のアナリスト会社がレーティングを報告しています。
Novo Nordiskの最新のアナリストレーティングはNovo Nordiskです。(NYSE:NVO) の最新のアナリストレーティングはCICCによるもので、Novo NordiskのNovo Nordiskです。{actionCompany}}のoutperform評価です。
Novo Nordisk ASの最後のアップグレードは10 2, 2025日に行われ、HSBCは目標株価を$70に引き上げました。companyName}}のHSBCの以前のa holdは$70でした。
Novo Nordisk ASの最後の格下げは12 8, 2025日にArgus ResearchがNovo Nordisk ASの目標株価をN/AからN/Aに変更した時です。
アナリストは、公開財務諸表を調べたり、Novo Nordiskの役員や顧客に話を聞いたり、決算の電話会議を傍聴したりと、広範な調査を行った上で株価の格付けを行っています。ほとんどのアナリストは3ヶ月ごとにこの作業を行いますので、毎年1社につき4つの格付けを得ることになります。companyName}}の最終レーティングは1 9, 2026日に提出されましたので、次のレーティングは1 9, 2027日あたりに提出されるものと思われます。
レーティングは主観的なものであり変化しますが、最新のNovo Nordisk (NVO) (NVO) のレーティングは開始で、目標株価は$0.00から$73.50でした。現在の価格 Novo Nordisk ({{exchange}}) (NVO) の現在の取引価格は$62.74で、これはアナリストの予測レンジwithinです。
ブラウズ アナリスト評価と目標株価 全銘柄の
